a Signature Research Program in Cardiovascular and Metabolic Disorders , Duke-National University of Singapore Medical School , Singapore , Singapore.
b Department of Biomedical Engineering, Faculty of Engineering , University of Malaya , Kuala Lumpur , Malaysia.
Expert Opin Ther Targets. 2018 Mar;22(3):247-261. doi: 10.1080/14728222.2018.1439015.
New treatments are required to improve clinical outcomes in patients with acute myocardial infarction (AMI), for reduction of myocardial infarct (MI) size and preventing heart failure. Following AMI, acute ischemia/reperfusion injury (IRI) ensues, resulting in cardiomyocyte death and impaired cardiac function. Emerging studies have implicated a fundamental role for non-coding RNAs (microRNAs [miRNA], and more recently long non-coding RNAs [lncRNA]) in the setting of acute myocardial IRI. Areas covered: In this article, we discuss the roles of miRNAs and lncRNAs as potential biomarkers and therapeutic targets for the detection and treatment of AMI, review their roles as mediators and effectors of cardioprotection, particularly in the settings of interventions such as ischemic pre- and post-conditioning (IPC & IPost) as well as remote ischemic conditioning (RIC), and highlight future strategies for targeting ncRNAs to reduce MI size and prevent heart failure following AMI. Expert opinion: Investigating the roles of miRNAs and lncRNAs in the setting of AMI has provided new insights into the pathophysiology underlying acute myocardial IRI, and has identified novel biomarkers and therapeutic targets for detecting and treating AMI. Pharmacological and genetic manipulation of these ncRNAs has the therapeutic potential to improve clinical outcomes in AMI patients.
需要新的治疗方法来改善急性心肌梗死（AMI）患者的临床预后，以缩小心肌梗死（MI）面积并预防心力衰竭。AMI 发生后，会发生急性缺血/再灌注损伤（IRI），导致心肌细胞死亡和心脏功能受损。新的研究表明，非编码 RNA（microRNAs [miRNA]，最近还有长非编码 RNA [lncRNA]）在急性心肌 IRI 中起着重要作用。
在本文中，我们讨论了 miRNA 和 lncRNA 作为 AMI 检测和治疗的潜在生物标志物和治疗靶点的作用，综述了它们作为心脏保护的介质和效应物的作用，特别是在缺血预处理和后处理（IPC & IPost）以及远程缺血预处理（RIC）等干预措施中，以及强调了靶向 ncRNA 以缩小 MI 面积和预防 AMI 后心力衰竭的未来策略。
研究 miRNA 和 lncRNA 在 AMI 中的作用为急性心肌 IRI 的病理生理学提供了新的见解，并确定了用于检测和治疗 AMI 的新型生物标志物和治疗靶点。这些 ncRNA 的药理学和遗传学操作具有改善 AMI 患者临床预后的治疗潜力。
